Close

Horizon Pharma (HZNP) Announces ACTIMMUNE Phase 3 in FA Missed Primary Endpoint

December 8, 2016 7:01 AM EST Send to a Friend
Horizon Pharma plc (Nasdaq: HZNP) announced that the Phase 3 trial, STEADFAST (Safety, Tolerability and Efficacy of ACTIMMUNE Dose Escalation ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login